Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS: Low-dose titrated amitriptyline for irritable bowel syndrome as second-line treatment
2019-000324-17Phase 3Unknown
- Sponsor
- University of Leeds
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Amitriptyline with Placebo (2 arms). Primary endpoint: Primary: Global IBS symptoms at 6 months. Status: unknown.
02
Drugs
amitriptyline
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2019-000324-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000324-17.